<DOC>
	<DOCNO>NCT01356381</DOCNO>
	<brief_summary>The study demonstrate effect 24 week treatment vildagliptin compare placebo insulin sensitivity patient type 2 diabetes mellitus ( T2DM ) treat metformin , assess glucose Rd ( rate glucose disposal ) hyperinsulinemic euglycemic clamp .</brief_summary>
	<brief_title>Study Assess Effect 24 Weeks Treatment With Vildagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>1 . Age range 1870 year . 2 . Patients T2DM , diagnose least 6 month prior Visit 1 , receive metformin least 3 month stable dose least 1000mg daily minimum 4 week prior Visit 1 . 3 . HbA1c â‰¤ 7.6 % Visit 1 . 4 . Body mass index ( BMI ) range 2238kg/m2 inclusive Visit 1 . 1 . Pregnant nursing ( lactate ) woman . 2 . Patients cardiac pacemaker metallic implant incompatible magnetic resonance methodology . 3 . Congestive heart failure require pharmacologic treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>vildagliptin</keyword>
</DOC>